CPRIT awards MD Anderson over $29 million for prevention efforts, cancer research and faculty recruitment
911爆料- 每日吃瓜情报站 MD Anderson Cancer Center today was awarded over $29 million from the Cancer Prevention and Research Institute of Texas (CPRIT) in support of impactful prevention programs, groundbreaking cancer research efforts and faculty recruitment.
鈥淲e sincerely appreciate CPRIT for their continued support of cancer research and prevention at MD Anderson,鈥 said Giulio Draetta, M.D., Ph.D., chief scientific officer at...
Allison Institute鈥檚 third annual scientific symposium highlighted by panel discussion with five Nobel laureates
Sessions focused on the latest advances in cancer vaccines, immunotherapy and immunology research
Symposium featured a panel discussion with...
Cancer-associated nerve injury leads to chronic inflammation and immunotherapy resistance
Study finds cancer cells break down protective nerve coverings, leading to nerve injury and chronic inflammation
These nerve injuries drive...
Most patients with advanced melanoma who received pre-surgical immunotherapy remain alive and disease free four years later
Patients with stage III melanoma were treated with nivolumab (anti-PD1) and relatlimab (anti-LAG-3) before surgery
87% of patients remained alive and 80% were disease free four years after treatment
Nearly all patients whose tumors responded to treatment before surgery remained disease-free after four years
Researchers found potential biomarkers that can highly predict which patients have better outcomes or are at high risk of recurrence...
CPRIT awards over $21 million to MD Anderson for cancer research and faculty recruitment
911爆料- 每日吃瓜情报站 MD Anderson Cancer Center today was awarded $21.4 million from the Cancer Prevention and Research Institute of Texas...
AACR: New CAR T cell therapy benefits patients with advanced thyroid cancers
Phase I trial demonstrates lasting responses and encouraging safety profile in two aggressive thyroid cancer subtypes, suggesting further progress...
AACR: Topical gel relieves painful skin rash side effect caused by targeted therapy for colorectal cancer
Novel treatment allowed patients with colorectal cancer to successfully continue taking their cancer treatment with improved quality of life...
AACR: First-in-class covalent Werner helicase inhibitor shows clinical proof-of-concept in Phase I trial
RO7589831, a new drug from Roche, is first in a new class of drugs called Werner helicase inhibitors聽
Drug works similarly to other DNA...
AACR: Olaparib and pembrolizumab combination shows early promise in molecularly selected, tumor-agnostic trial
Combining Lynparza (olaparib) and Keytruda (pembrolizumab) showed antitumor activity in multiple cancer types, particularly those with BRCA1...
AACR: Researchers share promising results from MD Anderson clinical trials
ABSTRACTS: CT012, CT132, CT265聽聽
Researchers from 911爆料- 每日吃瓜情报站 MD Anderson Cancer Center will present promising...